⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30117075 | 0.80 | — | — | |
| SCHEMBL247697 | 0.80 | — | — | |
| SCHEMBL7186439 | 0.79 | — | — | |
| SCHEMBL9221700 | 0.79 | — | — | |
| SCHEMBL30660250 | 0.79 | — | — | |
| SCHEMBL15417545 | 0.79 | — | — | |
| SCHEMBL8246948 | 0.77 | — | — | |
| SCHEMBL10288542 | 0.77 | — | — | |
| SCHEMBL243605 | 0.77 | DPP7 (0.63) | — | |
| SCHEMBL13244684 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120005067-A | Gel cation exchange resin and preparation method and application thereof | 江苏金杉新材料有限公司 | 2025-05-16 | — | — | CN | claimed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | claimed |
| WO-2010065709-A2 | HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | KHAN AMIN (US) | 2010-06-10 | — | — | WO | claimed |
| CN-120005067-A | Gel cation exchange resin and preparation method and application thereof | 江苏金杉新材料有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3204011-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057713-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057713-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045943-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | NAUREX, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004309-A1 | Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof | KHAN AMIN (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2010065709-A2 | HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF | KHAN AMIN (US) | 2010-06-10 | — | — | WO | disclosed |